Role of endothelin receptors for renal protection and survival in hypertension: Waiting for clinical trials

Hypertension

Volumn 48, Issue 5, 2006, Pages 834-837

  Barton, Matthias ^a   Mullins, John J ^b   Bailey, Matthew A ^b   Kretzler, Matthias ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVOSENTAN; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; HYDRALAZINE; SPP 301; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EDITORIAL; EXPERIMENTAL ANIMAL; HEART LEFT VENTRICLE; HUMAN; HYPERTENSION; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL;

ANIMALS; HUMANS; HYPERTENSION, RENAL; KIDNEY; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ENDOTHELIN;

EID: 33750233432     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000245138.09687.8a     Document Type: Editorial

References (38)

1. Remuzzi G, Chiurchiu C, Ruggenenti P. Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int. 2004;66(suppl):S90-S96.
2. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003;83:253-307.
3. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69:2131-2147.
4. Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Leiter LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Herbert C, Milot A, Stone JA, Burgess E, Hemmelgarn B, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM, Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II-therapy. Can J Cardiol. 2006;22:583-593.
5. Deferrari G, Ravera M, Deferrari L, Vettoretti S, Ratto E, Parodi D. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers. J Am Soc Nephrol. 2002;13(suppl 3):S224-S229.
6. Fogo AB. Progression versus regression of chronic kidney disease. Nephrol Dial Transplant. 2006;21:281-284.
7. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116:288-296.
8. Barton M, Shaw S, d'Uscio LV, Moreau P, Luscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun. 1997;238:861-865.
9. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist. Circulation. 1997;96:1593-1597.
10. Ballew JR, Fink GD. Role of endothelin ETB receptor activation in angiotensin II-induced hypertension: effects of salt intake. Am J Physiol Heart Circ Physiol. 2001;281:H2218-H2225.
11. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature (Lond). 1990;344:541-544.
12. Whitworth CE, Veniant MM, Firth JD, Cumming AD, Mullins JJ. Endothelin in the kidney in malignant phase hypertension. Hypertension. 1995;26:925-931.
13. Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, Belloni AS, Bahcelioglu M, Nussdorfer GG, Pessina AC. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vasc Biol. 2000;20:949-956.
14. Rothermund L, Pinto YM, Hocher B, Vetter R, Leggewie S, Kobetamehl P, Orzechowski HD, Kreutz R, Paul M. Cardiac endothelin system impairs left ventricular function in renin-dependent hypertension via decreased sarcoplasmic reticulum Ca(2+) uptake. Circulation. 2000;102:1582-1588.
15. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, McGrath I, Kotelevtsev Y, Mullins JJ. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem. 2001;276:36727-36733.
16. Vaneckova I, Kramer HJ, Bäcker A, Vernerová Z, Opoĉenský M, Cervenka L. Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension. 2005;46:969-974.
17. Opoĉenský M, Kramer HJ, Bäcker A, Vernerová Z, Eis V, Ĉervenka L, Čertíková Chábová V, Tesar. V, Vaněčková I. Late-onset endothelin-A receptor blockade reduces podocyte injury in homozygous Ren-2 rats despite severe hypertension. Hypertension. 2006;48:965-971.
18. Bachmann S, Peters J, Engler E, Ganten D, Mullins J. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int. 1992;41:24-36.
19. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension. 2004;44:974 -981.
20. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006;47:1084-1093.
21. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005;16:3306-3314.
22. Kretzler M. Role of podocytes in focal sclerosis: defining the point of no return. J Am Soc Nephrol. 2005;16:2830-2832.
23. Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C, Galbusera M, Gastoldi S, Mundel P, Remuzzi G, Benigni A. In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol. 2005;166:1309-1320.
24. Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, Bonomelli M, Mundel P, Endlich K, Remuzzi A, Remuzzi G. Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol. 2006;168:1073-1085.
25. Liang XB, Ma LJ, Naito T, Wang Y, Madaio M, Zent R, Pozzi A, Fogo AB. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol. 2006;17:1886-1895.
26. Fogo AB. New capillary growth: a contributor to regression of sclerosis? Curr Opin Nephrol Hypertens. 2005;14:201-203.
27. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105:925-933.
28. Tazawa N, Okada Y, Nakata M, Izumoto H, Takasu M, Takaoka M, Gariepy CE, Yanagisawa M, Matsumura Y. Exaggerated vascular and renal pathology in endothelin-B-receptor-deficient rats with subtotal nephrectomy. J Cardiovasc Pharmacol. 2004;44:S467-S470.
29. Barton M, Carmona R, Krieger JE, Goettsch W, Morawietz H, d'Uscio LV, Lattmann T, Luscher TF, Shaw S. Endothelin regulates angiotensin-converting enzyme in the mouse kidney. J Cardiovasc Pharmacol. 2000;36:S244-S247.
30. Hara M, Yanagihara T, Kihara I, Higashi K, Fujimoto K, Kajita T. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol. 2005;16:408-416.
31. Yu D, Petermann A, Kunter U, Rong S, Shankland SJ, Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol. 2005;16:1733-1741.
32. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol. 2006;17:2100-2105.
33. Jarad G, Cunningham J, Shaw AS, Miner JH. Proteinuria precedes podocyte abnormalities inLamb2 mice, implicating the glomerular basement membrane as an albumin barrier. J Clin Invest. 2006;116:2272-2279.
34. Wenzel RR, Mann J, Jürgens C, Yildirim I, Bruck H, Philipp T, Mitchell A. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. ASN Renal Week. 2005;F-FC093:Abstract.
35. Speedel. Speedel starts phase III study of SPP301 in diabetic nephropathy. 2005. Available at: http://www.speedel.com/section/7/subsections/4? &form_link=1120715251. Accessed July 19, 2006.
36. Myogen. Myogen initiates phase 3 clinical trial of darusentan in patients with resistant hypertension. 2006. Available at: http://www.myogen.com. Accessed July 13, 2006.
37. Barton M, d'Uscio LV, Shaw S, Meyer P, Moreau P, Luscher TF. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension. 1998;31:499-504.
38. Barton M, Vos I, Shaw S, Boer P, D'Uscio LV, Grone HJ, Rabelink TJ, Lattmann T, Moreau P, Luscher TF. Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and glomerulosclerosis. J Am Soc Nephrol. 2000;11:835-845.